Scientists refute aspects of UK Farm Scale GM study
05 December, 2003 by Graeme O'NeillA group of leading international agricultural and food scientists says increased food production by GM herbicide-tolerant crops could actually benefit the environment and enhance biodiversity in Britain and Europe by allowing unused farmland to rededicated as conservation reserves.
Novogen subsidiary raises US$10m
04 December, 2003 by Melissa TrudingerMarshall Edwards, the US subsidiary of Novogen (ASX:NRT), has raised US$10.1 million through the exercise of expiring warrants by shareholders.
Florigene to be sold to Suntory as Nufarm exits biotech
04 December, 2003 by Melissa TrudingerAustralian biotechnology pioneer Florigene, a subsidiary of Australian agricultural company Nufarm, is being sold off to long-time joint venture partner Suntory.
'Open-source biology' stance earns international honour
03 December, 2003 by Graeme O'NeillMaverick molecular geneticist Richard Jefferson is in New York this week to accept a prestigious Scientific American award as one of the magazine's 50 Global Technology Leaders of 2003.
New Bionomics mouse model shows epilepsy writ small
03 December, 2003 by Graeme O'NeillWhen Florey Institute epilepsy researcher Dr Steve Petrou showed the electroencephalogram trace to his colleague, Prof Sam Berkovic, the veteran clinician recognised it immediately.
Meditech raises $2.2m in share purchase plan
02 December, 2003 by Melissa TrudingerMeditech Research (ASX:MRL) has added AUD$2 million to its coffers through a shareholder purchase plan, bringing the total capital raised recently to $6.8 million.
US firm Biosite to use AGEN antibody
01 December, 2003 by Melissa TrudingerAgenix (ASX:AGX) subsidiary AGEN BioMedical has licensed its D-Dimer antibody and associated intellectual property to US point-of-care diagnostics company Biosite.
Peptech in cancer JV
01 December, 2003 by Melissa TrudingerPeptech (ASX:PTD) has entered into a joint venture with University of Sydney spin-off Biosceptre International to develop a range of diagnostic and therapeutic products based on a specific cancer marker expressed in a broad range of human cancers including skin, prostate, breast, bowel and uterine cancers.
The dark side of global warming
28 November, 2003 by Graeme O'NeillGlobal warming is making nights warmer around the globe and from pole to pole, and will have major effects on plant photosynthesis and productivity, according to Columbia University plant physiologist Dr Kevin Griffin.
BresaGen to spin off cell therapy business
28 November, 2003 by Melissa TrudingerBresaGen (ASX:BGN) is likely to become a holding company with stakes in several businesses, including a new stem cell company formed by the merger of BresaGen's cell therapy division with San Diego stem cell company CyThera, CEO John Smeaton told the company's AGM yesterday.
Norwood expects revenues from next month
28 November, 2003 by Melissa TrudingerNorwood Abbey (ASX:NAL) executive chairman Peter Hansen told shareholders at the company's AGM yesterday that the first revenues from the company's laser assisted drug delivery device would flow into the company in late December or early January.
AgGenomics ties up A2 milk DNA profiling deal
27 November, 2003 by Melissa TrudingerAgGenomics, a joint venture company owned by Melbourne-based Genetic Technologies (ASX:GTG) and the Victorian government, has been selected as the exclusive Australian provider of DNA profiling services for the selection of A2 dairy cattle for New Zealand company A2 Corporation.
BioAngels makes first local investment
27 November, 2003 by Melissa TrudingerMembers of South Australia's BioAngels have made their first investment into the South Australian bioscience sector, selecting Australian Orthopaedic Innovations from more than 20 applications.
Rockeby Biomed readies for IPO
26 November, 2003 by Melissa TrudingerDiagnostics company Rockeby Biomed is readying itself to float on the ASX in a back door listing through Carbine Corporation.
pSvida acquisition opens diagnostic pathway
26 November, 2003 by Melissa TrudingerPerth-based nanomaterials specialist pSivida (ASX:PSD) has acquired the rights to use porous silicon mirror technology from German research agency Forschungszentrum Julich.
